The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) from Elite Pharmaceuticals Inc (OTCBB: ELTP) for its methadone hydrochloride 5 mg and 10 mg tablets, the company revealed on Monday.
Glenmark Pharmaceuticals Inc (NSE: GLENMARK), Elite's marketing alliance partner, will sell and distribute the product, paying Elite manufacturing and licence fees.
Methadone is indicated for the management of pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate.
The drug can also be used for maintenance treatment of opioid addiction (heroin or other morphine-like drugs) in conjunction with appropriate social and medical services.
Annual retail sales for brand and generic methadone products are approximately USD30m, according to QuintilesIMS Health data.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval